Multicenter evaluation of the first automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsia

Clinical Biochemistry

Volumn 43, Issue 9, 2010, Pages 768-770

  Schiettecatte, J ^a   Russcher, H ^b   Anckaert, E ^a   Mees, M ^a   Leeser, B ^c   Tirelli, A S ^d   Fiedler, G M ^e   Luthe, H ^f   Denk, B ^g   Smitz, J ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Labor Alfredstrasse   (Germany)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^e UNIVERSITY OF LEIPZIG   (Germany)

^f UNIVERSITY OF GÖTTINGEN   (Germany)

^g ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

Angiogenic factors; Immunoassay; Placental growth factor; Preeclampsia; Soluble VEGFR 1

Indexed keywords

PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1;

ACCURACY; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HELLP SYNDROME; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; INTERRATER RELIABILITY; MALE; PREECLAMPSIA; PRIORITY JOURNAL; REPRODUCIBILITY; SECOND TRIMESTER PREGNANCY; SENSITIVITY AND SPECIFICITY; THIRD TRIMESTER PREGNANCY;

ADULT; AUTOMATION; FEMALE; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; MEMBRANE PROTEINS; OBSERVER VARIATION; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; PREGNANCY TRIMESTERS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 77952953001     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.02.010     Document Type: Article

References (12)

1. Roberts J.M., Cooper D.W. Pathogenesis and genetics of preeclampsia. Lancet 2001, 357:53-56.
2. Redman C.W., Sargent I.L. Latest advances in understanding preeclampsia. Science 2005, 308:1592-1594.
3. Maynard S.E., Min J.Y., Merchan J., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 2003, 111:649-658.
4. Levine R.J., Maynard S.E., Qian C., et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 2004, 350:672-683.
5. Levine R.J., Lam C., Qian C., et al: Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992-1005. Erratum in: N Engl J Med 2006;355:1840.
6. Staff A.C., Braekke K., Harsem N.K., Lyberg T., Holthe M.R. Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia. Eur. J. Obstet. Gynecol. Reprod. Biol. 2005, 122:33-39.
7. Hertig A., Berkane N., Lefevre G., et al. Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. Clin. Chem. 2004, 50:1702-1703.
8. Wikström A.K., Larsson A., Eriksson U.J., Nash P., Nordén-Lindeberg S., Olovsson M. Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet. Gynecol. 2007, 109:1368-1374.
9. Lam C., Lim K.H., Karumanchi S.A. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension 2005, 46:1077-1085.
10. Verlohren S., Galindo A., Schlembach D., et al. An automated method for the determination of the sFlt-1/PlGF ratio in the assessment of preeclampsia. Am. J. Obstet. Gynecol. 2009, 201:e1-1.e11.
11. Schneider E., Gleixner A., Hänel R., et al. Technical performance of the first fully automated assays for human soluble fms-like tyrosine kinase 1 and human placental growth factor. Z. Geburtshilfe Neonatol. 2009, 213:69.
12. Gunsilius E., Petzer A., Stockhammer G., et al. Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology 2000, 58:169-174.